No abstract available.
Nausea* ; Ondansetron* ; Vomiting*

We encountered a case of an accidental epidural injection of ondansetron through an epidural catheter. No neurological complications were noted. This case highlights the need for more attention to minimize the risk of epidural injections.
Catheters ; Injections, Epidural* ; Ondansetron*

No abstract available.
Ondansetron* ; Postoperative Nausea and Vomiting*

No abstract available.
Cisplatin* ; Humans ; Nausea* ; Ondansetron* ; Vomiting*

No abstract available.
Antiemetics* ; Cisplatin* ; Dexamethasone* ; Humans ; Lorazepam* ; Metoclopramide* ; Ondansetron*

No abstract available.
Antiemetics* ; Drug Therapy, Combination* ; Humans ; Ondansetron*

OBJECTIVE: We compared the impact of chemotherapy-induced nausea and vomiting (CINV) on patients of an aprepitant regimen with an ondansetron regimen, for antiemetic efficacy after highly emetogenic chemotherapy (HEC). METHODS: The study was performed prospective on 61 patients who is diagnosed initially the gynecological cancer during chemotherapy at Gospel hospital of Kosin university between March 2007 and October 2007. The study was divided according to an aprepitant/ondansetron regimen. The efficacy of controlling acute (during the 24 hours after chemotherapy) /delayed (day 2 days thought 5) nausea, vomiting and adverse effects were compared. Statistical analysis was performed using the chi-square test. RESULTS: The efficacy of controlling nausea with an aprepitant regimen and an ondansetron regimen was 86.7%, 83.9% in acute periods (Pvalue= 0.742) and 99%, 83.9% in delayed periods (P-value=0.083), respectively. The efficacy of controlling vomiting with an aprepitant regimen and an ondansetron regimen was 93.3%, 90.3% in acute periods (P-value=0.809) and 96.7%, 83.9% in delayed periods (Pvalue= 0.034), respectively. The efficacy of controlling delayed vomiting with an aprepitant regimen reported significantly. The common adverse effects in both groups were not significantly. CONCLUSION: The regimen including aprepitant was superior in preventing CINV as compared with a regimen in which both ondansetron and dexamethasone were given delayed periods in patients receiving chemotherapy
Dexamethasone ; Humans ; Morpholines ; Nausea ; Ondansetron ; Prospective Studies ; Vomiting

OBJECTIVE: We compared the impact of chemotherapy-induced nausea and vomiting (CINV) on patients of an aprepitant regimen with an ondansetron regimen, for antiemetic efficacy after highly emetogenic chemotherapy (HEC). METHODS: The study was performed prospective on 61 patients who is diagnosed initially the gynecological cancer during chemotherapy at Gospel hospital of Kosin university between March 2007 and October 2007. The study was divided according to an aprepitant/ondansetron regimen. The efficacy of controlling acute (during the 24 hours after chemotherapy) /delayed (day 2 days thought 5) nausea, vomiting and adverse effects were compared. Statistical analysis was performed using the chi-square test. RESULTS: The efficacy of controlling nausea with an aprepitant regimen and an ondansetron regimen was 86.7%, 83.9% in acute periods (Pvalue= 0.742) and 99%, 83.9% in delayed periods (P-value=0.083), respectively. The efficacy of controlling vomiting with an aprepitant regimen and an ondansetron regimen was 93.3%, 90.3% in acute periods (P-value=0.809) and 96.7%, 83.9% in delayed periods (Pvalue= 0.034), respectively. The efficacy of controlling delayed vomiting with an aprepitant regimen reported significantly. The common adverse effects in both groups were not significantly. CONCLUSION: The regimen including aprepitant was superior in preventing CINV as compared with a regimen in which both ondansetron and dexamethasone were given delayed periods in patients receiving chemotherapy
Dexamethasone ; Humans ; Morpholines ; Nausea ; Ondansetron ; Prospective Studies ; Vomiting

No abstract available.
Drug Therapy, Combination* ; Metoclopramide* ; Ondansetron* ; Prospective Studies* ; Vomiting*

BACKGROUND:Rocuronium is given for precurarization, timing or priming before the induction of anesthesia. The incidence of pain on injecting rocuronium is high and can be very distressing. The goal of this study was to evaluate whether pretreating lidocaine, fentanyl, or ondansetron i.v. can decrease the incidence and severity of injection pain. METHODS: One hundred and fifty patients were randomly allocated into five groups: patients in groups I, II, III, IV, and V received saline (3 ml), lidocaine 30 mg, lidocaine 50 mg, fentanyl 100microgram, or ondansetron 4 mg after manually occluding the forearm. The occlusion was released and rocuronium 0.6 mg/kg was injected. The patients were then observed and asked whether they had pain in the arm, and responses were assessed. RESULTS: The mean (median) pain scores in gorups I, II, III, IV, and V were 1.9 (2), 1.0 (1), 0.73 (1), 1.33 (1), and 1.2 (1), respectively. We found that 7%, 37%, 47%, 20%, and 20% of patients in groups I, II, III, IV and V reported no pain. Moderate to severe pain was seen in 60%, 33%, 20%, 40%, and 33% of patients in groups I, II, III, IV, and V, respectively. CONCLUSIONS: Lidocaine, fentanyl, and ondansetron reduced rocuronium injection pain. Of these drugs, lidocaine seems to be the most effective. Fentanyl and ondansetron proved less effective than lidocaine.
Anesthesia ; Arm ; Fentanyl* ; Forearm ; Humans ; Incidence ; Lidocaine* ; Ondansetron*